UCB announces initial clinical trial results involving patients taking certolizumab pegol for moderate to severe Crohn’s disease
22-Dec-2009 -
UCB announced the preliminary results of a recently completed Phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated fab’ fragment of a humanized anti-TNF alpha monoclonal antibody in patients with ...
clinical trials
inflammation
phase IIIb studies
+1